Administrative Burden, Class-Wide Impacts Are Among IRA Pitfalls
Executive Summary
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
You may also be interested in...
Medicare Part D Sponsors Grapple With Unknowns As Drug Price Negotiations Begin
CMS will monitor Medicare plans’ use of utilization management, and they are required to have the negotiated drugs on formulary, but the ‘ultimate question’ is how the plans will cover these negotiated drugs.
Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List
The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.